Children’s vaccine trials

Response of youngsters is being evaluated

Stanford Medicine is participating in clinical trials to evaluate the response of children under 12 to the Pfizer-BioNTech COVID-19 vaccine.

Max Perales, 8, receives the Pfizer COVID-19 vaccine from clinic nurse manager Rich Brotherton in June 2021 as part of a trial of the vaccine at Stanford Medicine in children 5-11 years old. (Photo by Steve Fisch)

Since May, researchers have tested whether the vaccine produces an immune response and prevents COVID-19 in children 5 through 11 years old.

The Stanford study site is also evaluating vaccine dosages for children 6 months through 4 years old.

Final results for the older age group are expected later this year.

“Children under 18 make up about a quarter of the U.S. population, so if we want to get the virus under control, we really need to include them,” said Yvonne Maldonado, MD, who is running the trials’ Stanford site.

Maldonado is the Taube Professor in Global Health and Infectious Diseases at Stanford.

Erin Digitale is the pediatrics science writer in the Office of Communications. Email her at

email Email the author

Additional Reading

Righting decades of wrong

In efforts to address racial inequity and medical mistrust, Stanford researchers and clinicians are redesigning health care strategies and implementing new approaches to reach marginalized communities.


Adventures of the mind

Struggling to clear the fog of his father’s advancing dementia, a Stanford Medicine physician discovers the power of the taste of a favorite meal to awaken memories.